{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T19:28:11Z","timestamp":1763580491488,"version":"3.28.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03369-3","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T15:02:47Z","timestamp":1726066967000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do interleukin-17 and interleukin-23 inhibitors alter the coagulation parameters in psoriasis patients?: A retrospective study"],"prefix":"10.1007","volume":"316","author":[{"given":"Simge","family":"\u00dcnal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu\u011fcan","family":"Y\u00fcksek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan Demirel","family":"\u00d6\u011f\u00fct","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema Ko\u00e7","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"Erba\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"G\u00f6kyayla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"3369_CR1","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590","journal-title":"BMJ"},{"key":"3369_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"W-H Boehncke","year":"2018","unstructured":"Boehncke W-H (2018) Systemic inflammation and Cardiovascular Comorbidity in Psoriasis patients: causes and consequences. Front Immunol 9:579","journal-title":"Front Immunol"},{"key":"3369_CR3","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H (2019) Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and Networ. J Immunol Res 2019:2546161","journal-title":"J Immunol Res"},{"key":"3369_CR4","doi-asserted-by":"publisher","first-page":"688861","DOI":"10.3389\/fimmu.2021.688861","volume":"12","author":"MJE Visser","year":"2021","unstructured":"Visser MJE, Tarr G, Pretorius E (2021) Thrombosis in Psoriasis: cutaneous cytokine production as a potential Driving Force of Haemostatic Dysregulation and subsequent Cardiovascular risk. Front Immunol 12:688861","journal-title":"Front Immunol"},{"issue":"3","key":"3369_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4103\/ijd.IJD_630_20","volume":"67","author":"MM Mir","year":"2022","unstructured":"Mir MM, Dogra D, Koul KK (2022) Hemostatic and Coagulation Profile in Psoriasis: A Hospital-based case control study. Indian J Dermatol 67(3):247\u2013251","journal-title":"Indian J Dermatol"},{"issue":"8","key":"3369_CR6","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1111\/bcp.15581","volume":"89","author":"RH Woods","year":"2023","unstructured":"Woods RH (2023) Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting System (FAERS). Br J Clin Pharmacol 89(8):2386\u20132395","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3369_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2340\/00015555-0456","volume":"88","author":"O Karabudak","year":"2008","unstructured":"Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y (2008) Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol 88(4):337\u2013340","journal-title":"Acta Derm Venereol"},{"key":"3369_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2015.04.023","volume":"446","author":"L Chandrashekar","year":"2015","unstructured":"Chandrashekar L, Rajappa M, Revathy G, Sundar I, Munisamy M, Ananthanarayanan PH et al (2015) Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin Chim Acta 446:181\u2013185","journal-title":"Clin Chim Acta"},{"key":"3369_CR9","doi-asserted-by":"crossref","unstructured":"Conic RRZ, Damiani G, Schrom KP, Ramser AE, Zheng C, Xu R et al (2020) Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. ;9(1)","DOI":"10.3390\/jcm9010186"},{"issue":"1","key":"3369_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15569527.2023.2275020","volume":"43","author":"M Esen","year":"2024","unstructured":"Esen M (2024) The effect of IL17 and IL23 inhibitors on hematological parameters and C-reactive protein in psoriasis patients. Cutan Ocul Toxicol 43(1):38\u201345","journal-title":"Cutan Ocul Toxicol"},{"issue":"2","key":"3369_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/09546634.2020.1801975","volume":"33","author":"A Ataseven","year":"2022","unstructured":"Ataseven A, Temiz SA, Eren G, \u00d6zer \u0130, Dursun R (2022) Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat 33(2):1091\u20131096","journal-title":"J Dermatolog Treat"},{"issue":"7","key":"3369_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3349\/ymj.2022.63.7.632","volume":"63","author":"Y Park","year":"2022","unstructured":"Park Y, Shim Y, Kwon I, Lee HW, Nam HS, Choi H-J et al (2022) Effects of Interleukin-17A on the early stages of arterial thrombosis in mice. Yonsei Med J 63(7):632\u2013639","journal-title":"Yonsei Med J"},{"issue":"4","key":"3369_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/hematolrep15040069","volume":"15","author":"A Gidaro","year":"2023","unstructured":"Gidaro A, Delitala AP, Manetti R, Caccia S, Soloski MJ, Lambertenghi Deliliers G et al (2023) Platelet microvesicles, inflammation, and coagulation markers: a pilot study. Hematol Rep 15(4):684\u2013695","journal-title":"Hematol Rep"},{"issue":"5","key":"3369_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","volume":"139","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, Koenig W, Pinter A, K\u00f6rber A et al (2019) Impact of Secukinumab on endothelial dysfunction and other Cardiovascular Disease parameters in Psoriasis patients over 52 weeks. J Invest Dermatol 139(5):1054\u20131062","journal-title":"J Invest Dermatol"},{"issue":"4","key":"3369_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM (2017) Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 176(4):890\u2013901","journal-title":"Br J Dermatol"},{"issue":"3","key":"3369_CR16","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.thromres.2015.01.003","volume":"135","author":"E Campello","year":"2015","unstructured":"Campello E, Spiezia L, Zabeo E, Maggiolo S, Vettor R, Simioni P (2015) Hypercoagulability detected by whole blood thromboelastometry (ROTEM\u00ae) and impedance aggregometry (MULTIPLATE\u00ae) in obese patients. Thromb Res 135(3):548\u2013553","journal-title":"Thromb Res"},{"issue":"6","key":"3369_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/bjd\/ljad039","volume":"188","author":"A Egeberg","year":"2023","unstructured":"Egeberg A, Thyssen JP (2023) Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration adverse events reporting System (FAERS). Br J Dermatol 188(6):793\u2013794","journal-title":"Br J Dermatol"},{"key":"3369_CR18","doi-asserted-by":"crossref","unstructured":"Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A et al (2024) Effectiveness, tolerability, and Drug Survival of Risankizumab in a Real-World setting: A Three-Year Retrospective Multicenter Study\u2014IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Clin Med. ;13(2)","DOI":"10.3390\/jcm13020495"},{"issue":"3","key":"3369_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG et al (2022) Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 186(3):466\u2013475","journal-title":"Br J Dermatol"},{"key":"3369_CR20","doi-asserted-by":"crossref","unstructured":"Mattay SS, Zamani M, Saturno D, Loftus EVJ, Ciorba MA, Yarur A et al (2023) Risk of major adverse Cardiovascular events in Immune-mediated inflammatory disorders on Biologics and Small molecules: Network Meta-Analysis. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc","DOI":"10.1016\/j.cgh.2023.09.033"},{"issue":"February","key":"3369_CR21","first-page":"1","volume":"15","author":"L Ding","year":"2024","unstructured":"Ding L, Chen C, Yang Y, Zhang X (2024) Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front Immunol 15(February):1\u201311","journal-title":"Front Immunol"},{"issue":"4","key":"3369_CR22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ et al (2017) The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol 77(4):650\u2013656e3","journal-title":"J Am Acad Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03369-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:11:07Z","timestamp":1729699867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03369-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3369"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03369-3","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This paper submitted with consent and knowledge of all co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent form was taken from all of the participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"613"}}